Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of the Combination of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Previously Untreated Follicular Lymphoma

NCT04450173 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT04450173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04450173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of the Combination of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Lead sponsor
University of California, Davis
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 24, 2021
Completion date
April 30, 2027
Enrollment
40 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage ii follicular lymphoma, ann arbor stage iii follicular lymphoma, ann arbor stage iv follicular lymphoma, grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3a follicular lymphoma